deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT03070392

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

Sponsor: Immunocore Ltd

Conditions Uveal Melanoma
Interventions Dacarbazine IMCgp100 Ipilimumab Pembrolizumab
Updated 41 times since 2017 Last updated: Jul 22, 2025 Started: Oct 16, 2017 Primary completion: Oct 13, 2020 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Uveal Melanoma and is currently ongoing. Immunocore Ltd leads this study, which shows 41 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2017 – ~Aug 2017 · 5 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Jun 2019 · 3 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Apr 2020 · 4 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Oct 2021 · 7 months · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Mar 2023 · 11 months · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Mar 2024 · 11 months · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~May 2025 · 4 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

41 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 36 earlier versions

  1. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Apr 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  6. Dec 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

  7. Oct 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Mar 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  9. Feb 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  10. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  11. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  12. Aug 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  13. May 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  14. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2

  15. Dec 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  16. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  17. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  18. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  19. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  20. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  21. Mar 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  22. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

  23. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  24. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  25. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  26. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  27. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  28. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  29. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  30. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE2

  31. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  32. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

  33. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  34. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  35. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  36. Mar 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Immunocore Ltd
Data source: Immunocore Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Atlanta, United States , Aurora, United States , Bebington, United Kingdom , Berlin, Germany , Boston, United States , Brussels, Belgium , Buffalo, United States , Chicago, United States , Cologne, Germany and 42 more locations